Enzalutamide for metastatic prostate cancer: a case report and review of the literature
10.3760/cma.j.cn112330-20210908-00010
- VernacularTitle:恩扎卢胺治疗转移性前列腺癌二例报告并文献复习
- Author:
Kechong ZHOU
1
;
Kang LIU
;
Xiao WANG
;
Li LIU
;
Xiaoqiang LIU
Author Information
1. 天津医科大学总医院泌尿外科 300052
- Keywords:
Prostate cancer;
Metastatic;
Enzalutamide;
Prostate-specific antigen
- From:
Chinese Journal of Urology
2021;42(Z2):33-36
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the efficacy and adverse reactions of enzalutamide in the treatment of metastatic prostate cancer(mPCa). Two male patients were reported, Patient 1 was hospitalized due to elevated PSA for 6 months and fatigue for 2 weeks. Tests on the admission showed that tPSA > 1 000 ng/ml, pathological of prostate biopsy: prostate acinar carcinoma, Gleason score 4+ 4=8, imaging examination revealed multiple metastases of prostate cancer throughout the body. Patient 2 was admitted to hospital due to cough, sputum, chest tightness and difficulty in defecation for more than 20 days, and the patient had radical surgery for prostate cancer five years ago. Tests on admission showed that tPSA > 100 ng/ml, fPSA>50 ng/ml. The patient was diagnosed as postoperative local recurrence of prostate cancer with bilateral pleural effusion, and cancer lymphangitis was considered. Both patients were treated with enzalumide combined with goseraline. Both patients were followed up for 6 months, PSA decreased significantly within half a year, general condition continued to improve, and they were well tolerated, no obvious adverse reactions occurred.
